Viiv

[anonymous]

Is anyone else pulling their hair out trying to get folks to use Cab? It’s been 3 months (plus the year+ market development), I’m frustrated as Hell. I feel like I’m much more frustrated than the Dovato reps, and I shouldn’t be.

 

[anonymous]

Is anyone else pulling their hair out trying to get folks to use Cab? It’s been 3 months (plus the year+ market development), I’m frustrated as Hell. I feel like I’m much more frustrated than the Dovato reps, and I shouldn’t be.

I had this discussion today with my manager - the Dovato reps are going on a 3 year pass of terrible performance and yet as Cab reps we are already feeling the heat for our poor performance

 

[anonymous]

You were hired on as the Navy Seals, remember? You had "injectable" experience. You were supposed to be the second coming. The company allowed you to remain employed for over a year without ever selling a single thing. Paid you monster salaries. DTG reps introduced you to customers and KOL's. Gave you office hours and held your hand for a year. ... You are compiling about being held accountable? I find it absolutely hilarious! ViiV is not laying off. They will work you out if not performing. Welcome to GSK!

 

[anonymous]

ViiV managers/reps/organization hold on for a pension, which is the problem.

Look at the stock. Everyone at ViiV works for GSK—and is very British in their denial.

Compare GSK stock to Gilead, Abbott, and a long list—over the past 5 yrs.

People who hang on for a pension—do not work, and the stock suffers for that reason.

 

[anonymous]

ViiV managers/reps/organization hold on for a pension, which is the problem.

Look at the stock. Everyone at ViiV works for GSK—and is very British in their denial.

Compare GSK stock to Gilead, Abbott, and a long list—over the past 5 yrs.

People who hang on for a pension—do not work, and the stock suffers for that reason.

Why are there always people fighting for these multi-billion companies that chew you up and spit you out without a second thought? Always someone complaining about how hard or not another person works. Worry about your work and let the chips fall!!!!

 

[anonymous]

Why are there always people fighting for these multi-billion companies that chew you up and spit you out without a second thought? Always someone complaining about how hard or not another person works. Worry about your work and let the chips fall!!!![/QUOTE
Should have never allowed an HIV company to be run by primary care Sanofi and thought anything would be successful. How detached can management be when they launch an HIv medication like a cardiologist injectable drug. There is the problem- lack of specialty experience and knowledge of the HIV market. There never should have been a 5 page enrollment form or a closed limited network of pharmacies that noone of the doctors use. Who’s genius idea was all that?
The ENTIRE team has implementation problems because of this bullshit process managed care created and you think this is normal to ignore the problem and say figure it out. Good luck

 

[anonymous]

I had this discussion today with my manager - the Dovato reps are going on a 3 year pass of terrible performance and yet as Cab reps we are already feeling the heat for our poor performance

I think after the poor Juluca launch and failed Dovato launch, a ton of pressure was moved to your team. CAB was a must home run, and so far you guys haven’t even touched the ball. The lackluster study data and nearly impossible office administration is not your fault, but GSK needed a ton out of this product and it’s not even going to come close.

 

[anonymous]

I think after the poor Juluca launch and failed Dovato launch, a ton of pressure was moved to your team. CAB was a must home run, and so far you guys haven’t even touched the ball. The lackluster study data and nearly impossible office administration is not your fault, but GSK needed a ton out of this product and it’s not even going to come close.

The heat is coming down which I completely get. Since July 2017 when we went to 3 per pod (the furthest thing from specialty sales ever) we have seen the following:

1. Recycled RSDs from respiratory who popped into ViiV, bury us in metrics, and then head to RTP. Plenty of examples where their districts were bottom 10% and they ran off talent and micromanaged the rest—and got promoted after 2 yrs.

2. Senior leaders who built the positive culture retired (Bill Collier, Marlon Pittman, etc.). Instead we got Pickett and the GSK crew.

3. Bailed on Triumeq while we had decent share for 2DR (Juluca, Dovato, Cabenuva, and the entire future pipeline combined don’t equal the amount that Triumeq/Tivicay LOST and are still losing. I doubt the entire 2DR sales—all drug sales combined will EVER reach over $200m total (net) while the several billion dollar Triumeq and Tivicay, 1-2 punch keeps bleeding a fortune. Of course TAF hurt Tivicay (remember when Tivicay+Descovy was what IDs said was the gold standard). Well—GILEAD listened and Biktarvy faced no competition (we were doomed).

4. Metrics hell with number of programs, calls, bathroom breaks literally micromanaged. And the never break your 3-4 week routing ever.

5. Going from 3 up to 4 up. What next, can we go 5 up? That should fix things, lol.

At the end of the day, we lost all respect with IDs and in the HIV advocacy community for pushing the 2DR regimen (with 48wk data initially, then 96wk, etc.) when the standard of care was and is 3DR.

Why are we surprised? I am not. In hindsight I wish my RSD had pushed me out or let me take early retirement.

 

[anonymous]

Viiv is so focused on gilead as the competition thats is the tunnel vision they see. Soon to hire a prep sales force- to be like gilead

bad moves we don’t need more people stop it viiv

 

[anonymous]

The heat is coming down which I completely get. Since July 2017 when we went to 3 per pod (the furthest thing from specialty sales ever) we have seen the following:

1. Recycled RSDs from respiratory who popped into ViiV, bury us in metrics, and then head to RTP. Plenty of examples where their districts were bottom 10% and they ran off talent and micromanaged the rest—and got promoted after 2 yrs.

2. Senior leaders who built the positive culture retired (Bill Collier, Marlon Pittman, etc.). Instead we got Pickett and the GSK crew.

3. Bailed on Triumeq while we had decent share for 2DR (Juluca, Dovato, Cabenuva, and the entire future pipeline combined don’t equal the amount that Triumeq/Tivicay LOST and are still losing. I doubt the entire 2DR sales—all drug sales combined will EVER reach over $200m total (net) while the several billion dollar Triumeq and Tivicay, 1-2 punch keeps bleeding a fortune. Of course TAF hurt Tivicay (remember when Tivicay+Descovy was what IDs said was the gold standard). Well—GILEAD listened and Biktarvy faced no competition (we were doomed).

4. Metrics hell with number of programs, calls, bathroom breaks literally micromanaged. And the never break your 3-4 week routing ever.

5. Going from 3 up to 4 up. What next, can we go 5 up? That should fix things, lol.

At the end of the day, we lost all respect with IDs and in the HIV advocacy community for pushing the 2DR regimen (with 48wk data initially, then 96wk, etc.) when the standard of care was and is 3DR.

Why are we surprised? I am not. In hindsight I wish my RSD had pushed me out or let me take early retirement.

meanwhile viiv collects $$$ for all their products and don’t pay commission to the reps for their 2DR and Injectable products. Greed at it’s finest. No career path at Viiv- they only select a few puppets to swim upstream. Move on or become a primary care rep. Management is not present to the TAM’s they just have weekly meetings to discuss amongst themselves yet have never experienced a real week working in the field. Basing decisions on crappy computer generated reports and out of touch with HIV as a disease state and the patients.

 

[anonymous]

I am so disappointed in Viiv. I truly am unmotivated. This company doesn’t acknowledge Covid or care about doing things that meet providers where they are. I am sad to go to work and feel humiliated asking doctors to go through 3-6 weeks to get a prescription to their patients. This is not right for the HIV community to be asked to do this. Why are primary care managers from Sanofi insisting this is how you launch a primary care product and compare that to HIV?
Guess what sanofi your shit stinks and all of your convoluted mindsets around hubs and closed networks.
This is HIV and this path will never fly in the community. Don’t expect to see me working with no pay. I truly hate this company right now. We are all spending our days entering fake calls and prepping our resumes to go somewhere hard working adults can work and not be subjected to these humiliating bullshit conference calls. Bye

 

[anonymous]

I am so disappointed in Viiv. I truly am unmotivated. This company doesn’t acknowledge Covid or care about doing things that meet providers where they are. I am sad to go to work and feel humiliated asking doctors to go through 3-6 weeks to get a prescription to their patients. This is not right for the HIV community to be asked to do this. Why are primary care managers from Sanofi insisting this is how you launch a primary care product and compare that to HIV?
Guess what sanofi your shit stinks and all of your convoluted mindsets around hubs and closed networks.
This is HIV and this path will never fly in the community. Don’t expect to see me working with no pay. I truly hate this company right now. We are all spending our days entering fake calls and prepping our resumes to go somewhere hard working adults can work and not be subjected to these humiliating bullshit conference calls. Bye

meanwhile in fantasy land I am trying to imagine what brainwizard thinks any territory has an institution or office that is working up 30-50 patients to put on cabenuva. Then magically get all of them approved in the next 2-4 weeks to make Q2 bonus. News flash- if you don’t have 50 people that signed enrollments this week, kiss your bonus goodbye. Any effort you put in after this week will go un noticed.

 

[anonymous]

meanwhile in fantasy land I am trying to imagine what brainwizard thinks any territory has an institution or office that is working up 30-50 patients to put on cabenuva. Then magically get all of them approved in the next 2-4 weeks to make Q2 bonus. News flash- if you don’t have 50 people that signed enrollments this week, kiss your bonus goodbye. Any effort you put in after this week will go un noticed.

Finks says to get it done!! She said this is super easy to sell.

 

[anonymous]

I am so disappointed in Viiv. I truly am unmotivated. This company doesn’t acknowledge Covid or care about doing things that meet providers where they are. I am sad to go to work and feel humiliated asking doctors to go through 3-6 weeks to get a prescription to their patients. This is not right for the HIV community to be asked to do this. Why are primary care managers from Sanofi insisting this is how you launch a primary care product and compare that to HIV?
Guess what sanofi your shit stinks and all of your convoluted mindsets around hubs and closed networks.
This is HIV and this path will never fly in the community. Don’t expect to see me working with no pay. I truly hate this company right now. We are all spending our days entering fake calls and prepping our resumes to go somewhere hard working adults can work and not be subjected to these humiliating bullshit conference calls. Bye

Youve been Sanofized. The only way out is to leave.

These bunch of losers all kissed each others asses and hid behind Plavix, Lovenox, and Lantus. None of which they had anything to do with.

If you want to see how this turns out, check with people at Mallinkodt, Ferring, Eisai & Novo where the rest of the Sanofi dregs landed.

 

[anonymous]

The heat is coming down which I completely get. Since July 2017 when we went to 3 per pod (the furthest thing from specialty sales ever) we have seen the following:

1. Recycled RSDs from respiratory who popped into ViiV, bury us in metrics, and then head to RTP. Plenty of examples where their districts were bottom 10% and they ran off talent and micromanaged the rest—and got promoted after 2 yrs.

2. Senior leaders who built the positive culture retired (Bill Collier, Marlon Pittman, etc.). Instead we got Pickett and the GSK crew.

3. Bailed on Triumeq while we had decent share for 2DR (Juluca, Dovato, Cabenuva, and the entire future pipeline combined don’t equal the amount that Triumeq/Tivicay LOST and are still losing. I doubt the entire 2DR sales—all drug sales combined will EVER reach over $200m total (net) while the several billion dollar Triumeq and Tivicay, 1-2 punch keeps bleeding a fortune. Of course TAF hurt Tivicay (remember when Tivicay+Descovy was what IDs said was the gold standard). Well—GILEAD listened and Biktarvy faced no competition (we were doomed).

4. Metrics hell with number of programs, calls, bathroom breaks literally micromanaged. And the never break your 3-4 week routing ever.

5. Going from 3 up to 4 up. What next, can we go 5 up? That should fix things, lol.

At the end of the day, we lost all respect with IDs and in the HIV advocacy community for pushing the 2DR regimen (with 48wk data initially, then 96wk, etc.) when the standard of care was and is 3DR.

Why are we surprised? I am not. In hindsight I wish my RSD had pushed me out or let me take early retirement.

Collier and Pittman, were legends and put in the work that put many of us within a year or two (or a great early retirement package) from raising hands.

Sadly, I doubt anyone would disagree who was around pre-expansion 2017. If we had just gotten rid of the dead weight and stayed with 2 rep pods (and the floater), stuck with Triumeq and Tivicay, we would have outperformed and still perform better than we are now.

 

[anonymous]

Collier and Pittman, were legends and put in the work that put many of us within a year or two (or a great early retirement package) from raising hands.

Sadly, I doubt anyone would disagree who was around pre-expansion 2017. If we had just gotten rid of the dead weight and stayed with 2 rep pods (and the floater), stuck with Triumeq and Tivicay, we would have outperformed and still perform better than we are now.

definitely not understanding why abandon what they have except chasing Gilead. Which is exactly what they wanted and viiv walked right into the trap. Why it is important for leaders to understand HIV.
Now we all suffer

 

[anonymous]

The heat is coming down which I completely get. Since July 2017 when we went to 3 per pod (the furthest thing from specialty sales ever) we have seen the following:

1. Recycled RSDs from respiratory who popped into ViiV, bury us in metrics, and then head to RTP. Plenty of examples where their districts were bottom 10% and they ran off talent and micromanaged the rest—and got promoted after 2 yrs.

2. Senior leaders who built the positive culture retired (Bill Collier, Marlon Pittman, etc.). Instead we got Pickett and the GSK crew.

3. Bailed on Triumeq while we had decent share for 2DR (Juluca, Dovato, Cabenuva, and the entire future pipeline combined don’t equal the amount that Triumeq/Tivicay LOST and are still losing. I doubt the entire 2DR sales—all drug sales combined will EVER reach over $200m total (net) while the several billion dollar Triumeq and Tivicay, 1-2 punch keeps bleeding a fortune. Of course TAF hurt Tivicay (remember when Tivicay+Descovy was what IDs said was the gold standard). Well—GILEAD listened and Biktarvy faced no competition (we were doomed).

4. Metrics hell with number of programs, calls, bathroom breaks literally micromanaged. And the never break your 3-4 week routing ever.

5. Going from 3 up to 4 up. What next, can we go 5 up? That should fix things, lol.

At the end of the day, we lost all respect with IDs and in the HIV advocacy community for pushing the 2DR regimen (with 48wk data initially, then 96wk, etc.) when the standard of care was and is 3DR.

Why are we surprised? I am not. In hindsight I wish my RSD had pushed me out or let me take early retirement.

this is true. I used to work at ViiV and the market was clear that HCPs were worried about resistance prior to 2DRs launching. Those concerns remained even after Juluca launched and there wasn’t any real interest in a 2DR. Ideally ViiV could have pivoted from being all in on 2DR and taken a portfolio sell approach that would have kept the focus on TRIUMEQ but also for a niche population of HCPs offer them 2DR as an option for their patients who are adherent to their drugs. ViiV went all in on the Dovato launch with naive patients even though the market was clear that they would be reluctant to prescribe 2DR to that type of patient. There is nothing wrong with having Dovato as an option, the miss was walking away from Triumeq and the standard of care when the market was clear that they were happy with the standard of care and had zero interest in shifting to a 2DR model.

 

[anonymous]

this is true. I used to work at ViiV and the market was clear that HCPs were worried about resistance prior to 2DRs launching. Those concerns remained even after Juluca launched and there wasn’t any real interest in a 2DR. Ideally ViiV could have pivoted from being all in on 2DR and taken a portfolio sell approach that would have kept the focus on TRIUMEQ but also for a niche population of HCPs offer them 2DR as an option for their patients who are adherent to their drugs. ViiV went all in on the Dovato launch with naive patients even though the market was clear that they would be reluctant to prescribe 2DR to that type of patient. There is nothing wrong with having Dovato as an option, the miss was walking away from Triumeq and the standard of care when the market was clear that they were happy with the standard of care and had zero interest in shifting to a 2DR model.

I agree with you - ViiV is a complete disaster with inferior products - we bring nothing to the table to help customers or patient’s.

 

[anonymous]

I agree with you - ViiV is a complete disaster with inferior products - we bring nothing to the table to help customers or patient’s.

Viiv, or GSK? Not sure how you can blame one and not the other when all the issues point to change of control.

Regardless, safe to say that Viiv brings more value than the GSK vax joint venture set up to distract from the rest of the circus. I cant wait for an adjuvant to gene therapies and one vaccine that remain unapproved by the FDA.

Actually, im more excited to see how the company pretends to be a real spec pharm bc is conducive to the narrative they need to fuel.

Maybe we can all figure out a way to be more diverse and less white to generate real value.

 

[anonymous]

Viiv, or GSK? Not sure how you can blame one and not the other when all the issues point to change of control.

Regardless, safe to say that Viiv brings more value than the GSK vax joint venture set up to distract from the rest of the circus. I cant wait for an adjuvant to gene therapies and one vaccine that remain unapproved by the FDA.

Actually, im more excited to see how the company pretends to be a real spec pharm bc is conducive to the narrative they need to fuel.

Maybe we can all figure out a way to be more diverse and less white to generate real value.

The dog is mostly black and i endorse the statement above.